According to filings with the U.S. Securities and Exchange Commission, Metagenomi is raising $100,000,000.00 in new funding. About Metagenomi: We harness the power of our proprietary metagenomics platform to create curative genetic medicines for patients. At Metagenomi, we believe genome editing tools with capabilities that go beyond the current technology landscape will be required in order to treat the vast majority of patients. Our goal is to unlock the full potential of genome editing by developing tools with new capabilities using novel cellular machinery discovered from the natural environment. Metagenomi was founded by pioneers in the field of metagenomics. They recognized the power that naturally evolved microbial systems could have in revolutionizing access to enhanced genome editing technologies to create potentially highly efficacious and curative genetic medicines. Our metagenomics discovery platform enables us to rapidly and effectively find and engineer highly active natural enzymes sourced from nature into genome editing tools that are highly specific, efficient, and have enhanced targetability. As the genetic medicine field continues to rapidly evolve, our platform positions us to be at the forefront of unlocking the full potential of genome editing through the continuous discovery of new editing systems and the development of the next wave of genetic medicines for patients.

To learn more about Metagenomi, visit http://metagenomi.co/

Contact:
Brian Thomas, Chief Executive Officer
510-871-4880
https://www.linkedin.com/in/b-c-thomas/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.